Replies to post #40803 on DNAprint Genomics (DNAG)

[manysevens]

About this drug approval issue ... I think it is fair to note that it is not just DNAG's drugs that will create revenue .. but also those of Biofrontera, which DNAG has (or will have) a 52% stake in. Biofrontera already has 3 drugs in Phase II clinical trials and the whole idea behind their deal with DNAPrint was to utilize DNAG's technology in order to expedite approval. http://www.biofrontera.com/IR/ir.html

Key phrase here ... "expedite approval" ... this is where the bigger pharm companies will want to get involved with DNAPrint.

Also of interest .. looking forward to hearing results from the Moffit trials.

"We've been collecting samples all along, but we
just now are in the process of enrolling an additional 100 patients into
a trial at the Moffitt Center, and over the next six to nine months
we'll be finalizing the data."

http://www.twst.com/ceos/ABN618.htm

Their nine months are up. And I think we can all expect the results to be positive when they do come out.